Recent Quotes (30 days)

You have no recent quotes
chg | %

Aurinia Pharmaceuticals Inc  

(Public, TSE:AUP)   Watch this stock  
Find more results for TSE:ISA
+0.01 (0.27%)
Apr 29 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 3.62 - 3.70
52 week 2.30 - 5.34
Open 3.64
Vol / Avg. 5,115.00/6,907.00
Mkt cap 118.38M
P/E     -
Div/yield     -
EPS -0.73
Shares 32.29M
Beta 2.97
Inst. own     -
May 13, 2016
Q1 2016 Aurinia Pharmaceuticals Inc Earnings Release (Estimated) Add to calendar
Mar 18, 2016
Q4 2015 Aurinia Pharmaceuticals Inc Earnings Release
Mar 7, 2016
Aurinia Pharmaceuticals Inc at Cowen Health Care Conference
Feb 11, 2016
Aurinia Pharmaceuticals Inc at Leerink Partners Global Healthcare Conference

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin -7128.07% -7917.87%
Operating margin -9691.23% -10034.04%
EBITD margin - -9371.06%
Return on average assets -44.95% -43.30%
Return on average equity -74.93% -69.13%
Employees 26 -
CDP Score - -


1203-4464 Markham St
+1-250-7084272 (Phone)
+1-250-7442498 (Fax)

Website links


Aurinia Pharmaceuticals Inc. (Aurinia) is a Canada-based is a clinical stage pharmaceutical company. The Company is focused on the development of its therapeutic immunomodulating drug candidate, voclosporin, which is a calcineurin inhibitor (CNI). Voclosporin is an oral drug, administered twice daily. It is structurally similar to cyclosporine A (CsA), but is chemically modified on the amino acid-1 residue. Voclosporin is used as a treatment for lupus nephritis (LN). LN is an inflammation of the kidney that if untreated or inadequately treated can lead to end-stage renal disease, the requirement for life-long dialysis, or death. The Company had completed two Phase III studies of voclosporin in patients with moderate to severe psoriasis. The Company had completed a Phase IIb clinical trial of voclosporin in de novo renal transplant recipients. The Company's wholly owned subsidiaries include Aurinia Pharmaceuticals, Inc. and Aurinia Pharma Limited.

Officers and directors

Richard M. Glickman LL.D. Executive Chairman of the Board
Age: 57
Charles A. Rowland Jr. Chief Executive Officer, Director
Age: 57
Dennis Bourgeault Chief Financial Officer, Corporate Secretary
Michael R. Martin Chief Operating Officer
Neil Solomons M.D. Chief Marketing Officer
Robert B. Huizinga Vice President - Clinical Affairs
Lawrence D. Mandt Vice President - Regulatory and Quality
Age: 57
Benjamin Rovinski Ph.D. Independent Director
Age: 58